NextGen Biomed US 2026

NOF CORPORATION, the leading commercial supplier of drug delivery products through R&D to commercial scale, provides activated PEGs for protein modification, single molecular PEGs for ADCs, Polysorbate 80 for formulation of biological medicines, PEG lipids and ionizable lipids for lipid nanoparticle (LNP) formulations. NOF's LNP platform composed of COATSOME® SS Series, novel biodegradable ionizable lipid, demonstrates superior endosomal escape and provides high protein expression with extremely low systemic toxicity. The platform can be applied to gene delivery, gene editing, nucleic acid vaccine and in vitro transfection. It is capable of encapsulating pDNA, siRNA and mRNA, and delivering these to various organs and tissues. NOF’s LNP platform is becoming adopted in clinical planning by NOF collaborators.

Sponsor biography coming soon

Sponsor biography coming soon

Sponsor biography coming soon

Whether you are in early discovery or further along the path to commercialization, SCIEX offers a comprehensive portfolio of hardware, software, and consumables. Our robust, reliable solutions help you get to the right answer the first time – and every time – to enable the next generation of biopharmaceuticals.

The Ajinomoto Group is a global company focused on the research, development, and manufacture of high quality products for the pharmaceutical, specialty chemical, nutraceutical, sports nutrition, and health & beauty industries, as well as food seasonings and consumer food products. Headquartered in Tokyo, the Ajinomoto Group has over 34,000 employees, maintaining operations in 36 countries and regions, and possessing a global production network of 117 factories. In fiscal 2022, sales were JPY 1,359 billion (USD 10.1 billion). Ajinomoto Bio-Pharma Services (Aji Bio-Pharma) is a fully integrated contract development and manufacturing organization (CDMO) with sites in Belgium, United States, Japan and India providing comprehensive development, cGMP manufacturing and aseptic fill finish services for small and large molecule APIs and intermediates.

Sponsor biography coming soon

Alloy Therapeutics accelerates the drug discovery process by providing access to best-in-class foundational drug discovery platforms, services, and company creation capabilities. Alloy Therapeutics has developed novel strains for fully human antibody discovery and created innovative technology to support a multitude of modalities that can help to quickly identify candidates. Leveraging our world class scientists, Alloy therapeutics platforms and services enables you to build a more robust antibody-based therapeutic pipeline.

Sponsor biography coming soon

ATEM Structural Discovery is an innovation leader in the field of next-generation analytical and 3D Structure determination based cryo-EM technology.

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 2,500 biotech and pharma companies worldwide. Contact us: +1(732)790-8340, or info@biointron.com. Visit our website: www.biointron.com

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. That’s why we pioneered SYNTAX™, the world’s first benchtop DNA printer powered by revolutionary enzymatic technology. With SYNTAX™, labs are empowered to print their own synthetic oligos – a dramatically faster and environmentally-friendly alternative to today’s outsourced, chemical-based DNA synthesis model. SYNTAX™ puts you in control of your workflows while giving you autonomy over your designs and yielding faster access to results. That means more time to unleash your curiosity and solve tough problems. We’re helping you get back to doing what you love. It starts with DNA on demand.

About Fluidic Sciences and Sphere Bio Fluidic Sciences develops transformative in‑solution technologies for protein interaction analysis. Its flagship Fluidity One‑M instrument leverages Microfluidic Diffusional Sizing (MDS) to measure binding affinity, stoichiometry, size, and concentration without immobilization—directly in complex backgrounds such as serum, plasma, and lysate. Sphere Bio is a Fluidic Sciences brand. Its technology develops and manufactures single‑cell analysis and monoclonality assurance systems that enable researchers to find, analyze, and isolate the most valuable cells with speed and precision. Its proprietary picodroplet microfluidics and Cyto‑Mine® Chroma multiplexing platform power applications across antibody discovery, cell line development, cell engineering, and cell therapy.

GeneFrontier is a Japan-based biotech company offering PUREfrex®, a customizable cell-free protein expression system for biologics R&D, enabling high-throughput screening, protein production, and AI/ML-driven discovery.

Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,700 employees and has served more than 200,000 customers across over 100 countries and regions.

Sponsor biography coming soon

Unlock the Future of Therapeutics with Key2Meds: At Key2Meds, we empower biopharmaceutical companies to accelerate drug discovery and development through innovative platforms and tailored solutions. Partner with us to transform your next breakthrough into reality. 1. Nanobody Discovery Platform: Is your monoclonal antibody meeting its potential? Explore the advantages of nanobodies—superior tumor penetration, bi-specific fusion capabilities, and cutting-edge expertise in nanobody development. Phage Display Platform: Target complex multi-pass membrane proteins (GPCRs, ion channels, transporters) with proven success across 30+ therapeutic targets. Several nanobody-derived candidates are already advancing in clinical trials. Yeast Display System: Rapidly identify and screen lead nanobody candidates in just 2–3 weeks, with integrated functional assays to select molecules based on desired biological activity. Single B Cell Platform: Isolate antigen-reactive B cells with over 90% specificity and generate pre-validated nanobody leads within seven days—ensuring speed and accuracy in your discovery pipeline. 2. Next-Generation ADC Payloads & Linkers: Worried about ADC payload toxicity? Our proprietary N-myristoltransferase inhibitor (NMTi)-based payloads offer targeted synthetic lethality against tumor tissues, sparing healthy cells to maximize safety. Optimized NMTi Payloads: Expand beyond traditional small-molecule toxins with novel agents designed for oncology, opening new therapeutic possibilities. Advanced Linker Design: Enhance payload stability and controlled release, driving improved efficacy and safety for your ADC programs. 3. Peptide Discovery Platform Seeking alternatives to ADCs or small molecules? Leverage our expertise to discover and optimize therapeutic peptides as innovative binders or inhibitors for your pipeline. Comprehensive Peptide Discovery: Develop peptides targeting protein-protein interactions, especially in cell-based applications. Optimization Services: Boost peptide stability, target specificity, blood-brain barrier penetration, and oral bioavailability for superior drug profiles. Versatile Integration: Seamlessly incorporate peptides into ADCs, PDCs, or other carriers for enhanced targeted therapies. End-to-End Preclinical Solutions: From initial discovery to full development, our suite of preclinical services ensures your biological therapeutics progress efficiently and effectively. Partner with Key2Meds—where innovation meets expertise. Let’s advance your next therapeutic together.

As a dedicated CDMO serving the healthcare industry, we bring life-enhancing and life-saving treatments to market for our customers and their patients. We are a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO. Today, we bring together a team of 19,000 colleagues across five continents to deliver integrated offerings that meet the complex needs of our global customer community.

Nicoya is advancing biopharmaceutical breakthroughs by equipping scientists with a powerful, integrated analytical platform for characterizing complex biologics. Following its acquisition of Applied Photophysics, Nicoya uniquely combines its pioneering Surface Plasmon Resonance (SPR) systems, including the high-throughput Alto™, with world-renowned technologies for protein structural analysis (Chirascan™ Circular Dichroism) and kinetic/stability studies (SX™ stopped-flow, SUPR-DSF™). This unified offering provides researchers with a comprehensive understanding of a biologic's critical quality attributes—function, structure, and stability—from a single, expert source. By enabling earlier, more informed decision-making and delivering high-quality data crucial for AI-driven drug development, Nicoya empowers partners to de-risk pipelines, accelerate the path to clinic, and bring life-changing therapies to patients more efficiently.

Nona Biosciences is a biotechnology company offering integrated solutions for antibody discovery and development. Leveraging our proprietary Harbour Mice® platforms, which generate fully human H2L2 and heavy chain-only antibodies (HCAbs), our approach supports a wide range of therapeutic formats. The H2L2 Open Access Platform enables rapid entry into discovery, while Modalities-on-Demand™ provides tailored support for bispecifics, ADCs, CAR-T, and TCEs. With capabilities spanning immunization, screening, engineering, and IND-enabling services, Nona empowers partners to move efficiently from idea to IND with flexibility and confidence.

Novilytic's Proteometer is transforming drug development and clone selection by removing sample preparation steps that were once industry standard. Their innovative technology fundamentally alters biopharmaceutical production by offering near-real-time molecular structure analysis. This decreases the time and cost of developing new medicines, ultimately helping to bring lifesaving treatments to market more quickly.

Octapharma Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 employees worldwide to support patients in 120 countries with products across three therapeutic areas: Immunotherapy, Hematology and Critical Care.

Founded in 2014, PAIA Biotech has developed a growing portfolio of high throughput assays for its patented detection technology using special microplates in small volumes. Several product lines have been launched for the platform, most recently developability assays for antibody discovery. We appreciate the support of our large network of customers and partners in developing these exciting novel assay solutions. In addition to off-the-shelf assay products PAIA Biotech GmbH offers the first glycan screening assay service that can cope with the sample numbers and turnaround requirements of cell culture labs. PAIA Biotech GmbH is based in the center of Europe, in Cologne/Germany

PipeBio makes biologics discovery easier and faster for scientists by helping them screen and analyze millions of sequences and identify key candidates on a cloud-native platform. PipeBio is part of Benchling’s R&D Cloud, software that powers the biotechnology industry. With Benchling, scientists can accelerate R&D and bring life-changing medicines and products to people faster. More than 200,000 scientists at over 1,300 companies and 7,500 academic and research institutions globally rely on Benchling to convert the complexity of biology into world-changing results. For more, please visit Benchling.com.

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live.

Rapid Novor helps researchers decode immunity so they can rapidly and effortlessly develop diagnostics, therapies and reagents. We develop new technology and offer services for: protein sequencing by mass spectrometry, polyclonal antibody sequencing, epitope mapping, antibody characterization by LC-MS, and SPR. The innovative next generation protein sequencing technology we’ve developed has the potential to unlock countless discoveries for human health.

Sapio Sciences' mission is to improve lives by accelerating discovery, and because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware (TM) lab informatics platform combining cloud-based LIMS, ELN, and Jarvis data solutions. Sapio serves some of the largest global and specialist brands, including biopharma, CRO/CDMOs and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, chemistry, stability, histopathology, and in vivo studies. Customers love Sapio's platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs. For more information, visit www.sapiosciences.com and follow us on LinkedIn.

SGS is the world’s leading inspection, verification, testing and certification company. With more than 90,000 employees, SGS operates a network of over 1,500 offices and laboratories around the world. The Life Science division serves pharmaceutical, biopharmaceutical, and medical device companies along the entire drug development pathway. With over 35 years’ experience as a global contract service organization, SGS provides integrated (bio)pharmaceutical development and testing solutions including clinical research, pharmaceutical development, biologics characterization, biosafety, and quality control testing for small and large molecules, raw materials, containers and finished products. SGS Vitrology provides a comprehensive range of biosafety services such as: virology, cell and molecular biology as well as microbiology and electron microscopy. Health Authorities, including the US FDA and the EMA, require companies to undergo safety testing demonstrating that cell banks, viral banks, raw materials, bulk harvests, and batches of clinical drug are free of bacteria, fungi, mycoplasma, viruses, and other potential contaminants. SGS Vitrology helps clients by ensuring product safety in satisfying these regulatory requirements. Our GLP/GMP facility is MHRA certified, and US FDA audited.

Teknova makes solutions possible. Since 1996, we have been innovating how critical reagents are manufactured for the life sciences industry. Our goal is to help our customers be more effective as they work to discover and develop novel therapies that can help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers, reagents, and water helps our customers seamlessly scale from RUO to GMP. Our headquarters are in Hollister, California, where we have over 180,000 square feet of state-of-the-art, ISO 13485-certified manufacturing facilities, complete with end-to-end automation. Our unique modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.

Thermo Fisher Scientific is a fully integrated, end-to-end CDMO and CRO partner, offering comprehensive drug development capabilities for small and mid-size biotechnology companies, as well as large pharmaceutical organizations. Through our Accelerator™ Drug Development approach, we deliver 360° drug development solutions spanning from concept to commercialization. Whether you’re a small biotech in the pre-IND phase or a mid-size biotech focused on scale-up, we have the equipment and expertise to speed up your journey to market. With our Biologics Path to IND platform, you’ll gain access to a streamlined cell line development process, a nine-month turnaround time from drug substance to drug product, and ongoing clinical trial support. To learn more about our 360° CDMO and CRO solutions, visit us at booth #23 at Biologics US.